PositiveID's ExcitePCR Named Major Player in Molecular
Diagnostics Industry Report
ExcitePCR's FireflyDX is designed to bring lab-based testing to
the point of need for real-time biological threat detection in less
than 30 minutes
Delray Beach, FL -- December 14, 2017 -- InvestorsHub NewsWire
-- PositiveID Corporation (the "Company") (OTC:
PSID), a life sciences company focused on detection and
diagnostics, announced today that its ExcitePCR Corporation
subsidiary has been named a major player in a new report titled,
"Global POC Molecular Diagnostics
Market Size, Status and Forecast 2022," by market research firm
Questale.
"It is an honor for ExcitePCR to be included in Questale's list
of major players in the point-of-care/point-of-need healthcare
diagnostics marketplace," said Lyle Probst, President and CEO of
ExcitePCR. "Through our predecessor company, we have been an active
participant in identifying and measuring airborne pathogens such as
anthrax for over 10 years. With the recent advancements we've made
to our FireflyDX technologies, we look forward to bringing these
real-time PCR-based testing and diagnostics systems to market next
year."
ExcitePCR's FireflyDX-Portable is designed for use in several,
multi-billion-dollar industries (including healthcare screening),
markets where molecular diagnostics are critical to ensure rapid
safety and treatment protocols. Unfortunately, today's existing
solutions for accurately identifying potential pathogens and
bio-threats, especially in-the-field at the
point-of-care/point-of-need, can sometimes take as long as several
hours to several days to provide results, dramatically delaying
what is often life-saving treatment, while also increasing costs,
both personal and financial. In addition, most state-of-the-art
polymerase chain reaction (PCR) solutions in use today for pathogen
detection typically require a professionally trained operator
working in a pristine laboratory setting and/or are heavy, bulky
and tied to a personal computer to function properly.
By contrast, ExcitePCR's FireflyDX-Portable is designed to be a
standalone, bookbag-sized bio-threat detection system that can be
operated by virtually anyone with minimal training yet still
produces highly accurate results. In addition, the
FireflyDX-Portable is expected to deliver results in under 30
minutes, including sample preparation (which generally takes the
most time in pathogen detection).
According to San-Francisco-based Questale, ExcitePCR is one of
the companies named in its recently published research report under
the category of infectious diseases testing. For more information
about the report, please contact Jesse Woodson at 415-830-6056 or
contact@questale.com.
About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics
company with an extensive patent portfolio. PositiveID develops
biological detection and diagnostics systems, specializing in the
development of microfluidic systems for the automated preparation
of and performance of biological assays. PositiveID is also a
leader in the mobile technology vehicle market, with a focus on the
laboratory market and homeland security. For more information on
PositiveID, please visit http://www.psidcorp.com, or connect
with PositiveID on Twitter, Facebook or LinkedIn.
On August 24, 2017, PositiveID Corporation and its wholly-owned
subsidiary PositiveID Diagnostics, Inc. (collectively, the
"Seller"), entered into an Asset Purchase Agreement ("APA") with
ExcitePCR Corporation. Pursuant to the APA, at closing, the Seller
will sell and deliver to ExcitePCR all assets used in connection
with the operation of the FireflyDX technology. For more
information on the APA, please read PositiveID's Form 8-K filed on
August 28, 2017, which can be found here.
Statements about PositiveID's future expectations, including the
likelihood that ExcitePCR is a major player in the global POC
molecular diagnostics market; the likelihood that FireflyDX is
designed to bring lab-based testing to the point of need for
real-time biological threat detection in less than 30 minutes; the
likelihood that ExcitePCR will bring these real-time PCR-based
testing and diagnostics systems to market next year; the likelihood
that FireflyDX is designed for use in several, multi-billion-dollar
industries (including healthcare screening); the likelihood that
ExcitePCR's FireflyDX-Portable is designed to be a standalone,
bookbag-sized bio-threat detection system that can be operated by
virtually anyone with minimal training yet still produces highly
accurate results; the likelihood that the FireflyDX-Portable is
expected to deliver results in under 30 minutes, including sample
preparation, which generally takes the most time in pathogen
detection; constitute "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934, and as that term is defined
in the Private Litigation Reform Act of 1995. Such forward-looking
statements involve risks and uncertainties and are subject to
change at any time, and PositiveID's actual results could differ
materially from expected results. These risks and uncertainties
include, without limitation, the Company's ability to complete the
development, testing and commercialization of the
FireflyDX-Portable and FireflyDX-Handheld; the Company's ability to
target the professional healthcare market; the Company's ability to
raise capital; the Company's and ExcitePCR's ability to close the
APA; as well as other risks. Additional information about these and
other factors that could affect the Company's business is set forth
in the Company's various filings with the Securities and Exchange
Commission, including those set forth in the Company's 10-K filed
on March 31, 2017, and 10-Qs filed on November 13, 2017, August 14,
2017, and May 15, 2017, under the caption "Risk Factors." The
Company undertakes no obligation to update or release any revisions
to these forward-looking statements to reflect events or
circumstances after the date of this statement or to reflect the
occurrence of unanticipated events, except as required by law.
Contact:
PositiveID Corporation
Allison Tomek
(561) 805-8044
atomek@psidcorp.com